Evidence map›Paper›PMID 34448148›Full record

ReviewPharmacoEconomics2021

Filgotinib for Moderate to Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Sabine E Grimm, Ben Wijnen, Rob Riemsma, Debra Fayter, Nigel Armstrong, Charlotte Ahmadu, Lloyd Brandts, Kate Misso, John R Kirwan, Jos Kleijnen and 1 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Sabine E GrimmDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands. sabine.grimm@mumc.nl.ORCID 0000-0002-2175-7999
Ben WijnenDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Rob RiemsmaKleijnen Systematic Reviews Ltd, York, UK.
Debra FayterKleijnen Systematic Reviews Ltd, York, UK.
Nigel ArmstrongKleijnen Systematic Reviews Ltd, York, UK.
Charlotte AhmaduKleijnen Systematic Reviews Ltd, York, UK.
Lloyd BrandtsDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Kate MissoKleijnen Systematic Reviews Ltd, York, UK.
John R KirwanEmeritus Professor of Rheumatic Diseases, University of Bristol, Bristol, UK.
Jos KleijnenKleijnen Systematic Reviews Ltd, York, UK.
Manuela A JooreDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Kleijnen Systematic Reviews (United Kingdom) · GBMaastricht University Medical Centre · NLMaastricht University · NLUniversity of Bristol · GB

Funding

Department of Health
6 · The paper itself

Abstract

The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Gilead) of filgotinib (Jyseleca

Indexed as

Arthritis, RheumatoidTechnology Assessment, BiomedicalCost-Benefit AnalysisHumansPyridinesQuality-Adjusted Life YearsTechnologyTriazolesGLPG0634PyridinesTriazoles

Identifiers

PMID34448148
PMCPMC8599377
OpenAlexW3194665371

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.